Other Events ·
Immuron Limited executed an exclusive distribution agreement with Calmino group AB to launch PROIBS® in the United…
IMRNImmuron Ltd
Immuron Limited executed an exclusive distribution agreement with Calmino group AB to launch PROIBS® in the United States. PROIBS® is a medical device for abdominal pain and digestive issues containing AVH200®, derived from Aloe barbadensis Mill., which has been available in European markets for over a decade. The U.S. digestive health supplement market is valued at $4.16 billion, with Immuron targeting a specific subset. This agreement expands Immuron's commercial presence following the product's launch in Australia during FY26. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.